Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T
Department of Urology, Shimane Medical University, Izumo, Japan.
Urol Int. 1996;56(3):163-8. doi: 10.1159/000282833.
To elucidate whether a significant difference in malignant potential between ureteropelvic transitional cell carcinoma (TCC) and bladder TCC is present, the argyrophilic nucleolar organizer region (AgNOR), nuclear DNA content and mean nuclear area (MNA) were evaluated in 32 ureteropelvic TCCs and 60 bladder TCCs, and were also compared with histological grade and stage. The parameters used were the mean AgNOR count (C-AgNOR), the percentage of cells exhibiting more than 3 AgNOR dots within nuclei (P-AgNOR), 2c deviation index (2cDI), 5c exceeding rate (5cER) and MNA. No significant difference in these 5 parameters was found between ureteropelvic and bladder TCCs. In addition, within each histological grade of tumor, no significant difference in each parameter between ureteropelvic and bladder TCCs was noted. Similarly, within pTa or pT1 TCCs, there was no significant difference in the parameters between ureteropelvic and bladder TCCs. On the other hand, invasive TCCs (pT2 and higher), the C-AgNOR and P-AgNOR were significantly higher in ureteropelvic than in bladder TCC (p < 0.05), while no significant difference in 2cDI, 5cFR and MNA was noted. These findings suggest that: (i) as a whole, the difference in malignant potential between ureteropelvic and bladder TCCs appears to be less significant, and (ii) factors other than the malignant potential of a tumor might contribute to the unfavorable clinical outcome in patients with ureteropelvic TCC.
为了阐明肾盂输尿管移行细胞癌(TCC)与膀胱TCC在恶性潜能上是否存在显著差异,我们对32例肾盂输尿管TCC和60例膀胱TCC的嗜银核仁组织区(AgNOR)、核DNA含量及平均核面积(MNA)进行了评估,并与组织学分级和分期进行了比较。所使用的参数包括平均AgNOR计数(C-AgNOR)、细胞核内出现超过3个AgNOR点的细胞百分比(P-AgNOR)、2c偏差指数(2cDI)、5c超标率(5cER)和MNA。肾盂输尿管TCC和膀胱TCC在这5个参数上未发现显著差异。此外,在每个肿瘤组织学分级内,肾盂输尿管TCC和膀胱TCC在每个参数上也未发现显著差异。同样,在pTa或pT1 TCC中,肾盂输尿管TCC和膀胱TCC在参数上也没有显著差异。另一方面,在浸润性TCC(pT2及更高分期)中,肾盂输尿管TCC的C-AgNOR和P-AgNOR显著高于膀胱TCC(p<0.05),而2cDI、5cFR和MNA未发现显著差异。这些发现表明:(i)总体而言,肾盂输尿管TCC和膀胱TCC在恶性潜能上的差异似乎不太显著;(ii)除肿瘤恶性潜能外的其他因素可能导致肾盂输尿管TCC患者临床预后不良。